Publisher: Bentham Science Publishers
E-ISSN: 1873-5592|10|8|707-715
ISSN: 1389-4501
Source: Current Drug Targets, Vol.10, Iss.8, 2009-08, pp. : 707-715
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Ketamine acts mainly as a N-methyl-D-aspartate receptor (NMDAr) antagonist. Originally developed as a general anesthetic, it is now seldom employed as such in richer countries due to the relatively high risk of psychotomimetic adverse effects. Recently, low-dose regimens in the range of 0.25-0.5 mg/kg as an initial bolus followed by 50-500 μg/kg/h have been proposed as an adjuvant for postoperative analgesia and for the reduction of exogenous opioid-induced hyperalgesia. In this review, we examine the evidence for clinical usefulness of perioperative ketamine infusion and its role in the context of general and/or regional anesthesia.
Related content
Low-dose dopamine not nephroprotective in ICU patients
Inpharma, Vol. 1, Iss. 1269, 2001-01 ,pp. :
Low-dose orlistat beneficial for moderately overweight patients
Inpharma, Vol. 1, Iss. 1558, 2006-01 ,pp. :